Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.
about
Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failureRecent developments in non-invasive cardiologyThe accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review.Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study.Evaluation of B-type natriuretic peptide for validation of a heart failure register in primary care.Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care.Clinical burden and health service challenges of chronic heart failureThe REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design.Echocardiographic and electrocardiographic characteristics of male and female squirrel monkeys (Saimiri spp.).Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations.Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis.The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure.Association of impedance cardiography parameters with changes in functional and quality-of-life measures in patients with chronic heart failure.Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population.N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.Evaluation of N-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein relationship with features of metabolic syndrome in high-risk subgroups for cardiovascular disease.Cost-effective strategies to screen for left ventricular systolic dysfunction in the community--a concept.N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shockIdentification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide.The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study.N-terminal pro-brain natriuretic peptide levels predict left ventricular systolic function in patients with chronic kidney disease.Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.Some heterogeneity factors affecting the B-type natriuretic peptides outcome: a meta-analysis.Encapsulated pheochromocytoma cells secrete potent noncatecholamine factorsCorrelation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failurePrimary care REFerral for EchocaRdiogram (REFER) in heart failure: a diagnostic accuracy study.Can we use B-type natriuretic peptides to monitor patients with heart failure?Development and initial validation of a simple clinical decision tool to predict the presence of heart failure in primary care: the MICE (Male, Infarction, Crepitations, Edema) rule.New insight into improvement of cardiovascular outcomes with intensive glycemic control in patients with metabolic syndrome and type 2 diabetes mellitus included.Natriuretic peptides: Diagnostic and therapeutic use.Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure.MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.B type natriuretic peptide testing: where are we now?Pulsatile hemodynamics and clinical outcomes in acute heart failure.An evolving picture.Biological serum markers in the management of pediatric pulmonary arterial hypertension.Hematological Parameters Outperform Plasma Markers in Predicting Long-Term Mortality After Coronary Angiography.N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea.
P2860
Q28535034-90B02E30-736E-4D0A-B6C6-9B501B958719Q30458413-4BB2BDCE-689A-4D22-9515-08BA9F08FAD6Q30484159-80166B92-19F7-4650-9623-36B67C13FD95Q30919400-58538D3E-FA2F-45A1-B7B1-AACB3865FC36Q33292472-C00CF95C-ADAC-4549-8B1F-D63AA70D2596Q33321054-5D94B46B-68A4-4DE4-AF2D-1C9B5D291EA1Q34035122-1171FB25-2C7E-47CF-A119-56781B59C6C3Q34461484-9AD55806-E5F8-40DF-9BDB-880B704EA570Q35031077-ED276919-7B6F-4F11-933B-CFE14FC3C54DQ35574253-F63FE0CA-6F5E-4829-B7EB-73773A04EDEFQ35581367-E8EC6C6A-87A7-4C05-AE2C-938CC700BD9AQ35582649-6582F8D5-C423-416F-BF59-B5E61469E6F7Q35678102-82B39A6B-FA1C-45F3-B7BF-AFF06537E7F7Q35717608-7DFB804E-7DC9-4FFD-836A-EBCC9A2DF763Q35741773-4C4D5962-46E0-4DAD-B71C-A87B43FCAF99Q36014317-072405BF-014A-4706-9169-6AECE7C00EB8Q36124913-CF920FDA-417D-4693-86E6-CD743C52A737Q36163932-30874034-EE90-458F-BF01-FBEC323546B9Q36232775-0D4DF519-38D6-4A36-939B-B19CDA4FB20DQ36392546-16FAFCF9-DAC2-455D-AF5D-98CAC251783DQ36707626-C707F352-F3CB-4559-BC9A-1EC7BD2B0EAFQ36790405-CE417616-87B5-4107-9010-E03D7E879202Q37078080-9055D235-E59B-4E82-ADA8-CDD0DFF9AB7BQ37108057-CE7CA9EB-962A-43AB-8E48-FFD1E2EED152Q37313438-E82A86FC-75EB-43B6-A46A-ECC1DB96CCCBQ37471620-B3F9E06F-F137-485C-863D-B37F6AD8F39FQ37477161-F761CF49-FB98-42F5-A648-7CDD12E5FB99Q37641033-21D7C66F-414F-42A5-A310-66D384501A56Q37755067-CE2D1C31-4305-415E-9F08-DA6ED0E2F599Q38020022-F38E1A93-0BA0-45CE-A6F6-050548E059C1Q38239036-CBE8B522-8D1F-41CC-95EA-0B474A10EB92Q39581832-4D34072E-6BBD-438C-8381-E45D7A6D931AQ40022124-2289F364-67CA-464B-8278-7C55E0A06552Q41368070-92929561-84CC-4922-B130-C0612A942ABDQ42706863-6DF8348E-24A4-4C07-A90F-2602E95C5000Q45255474-94630A7A-C3FE-416F-AF98-0AD63632BD3BQ46124512-84F8AB7F-79C9-48C3-AB58-0AF74414D824Q46743475-14816D09-71DA-4F85-9DE5-6143EF03D3A1Q47935350-5B990E04-2D38-402F-91BC-33B562D8B65FQ47973118-2ECDDA5A-43CC-4BAA-87D8-56428E861665
P2860
Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Reliability of N-terminal pro- ...... gh risk community populations.
@ast
Reliability of N-terminal pro- ...... gh risk community populations.
@en
type
label
Reliability of N-terminal pro- ...... gh risk community populations.
@ast
Reliability of N-terminal pro- ...... gh risk community populations.
@en
prefLabel
Reliability of N-terminal pro- ...... gh risk community populations.
@ast
Reliability of N-terminal pro- ...... gh risk community populations.
@en
P2093
P2860
P1433
P1476
Reliability of N-terminal pro- ...... gh risk community populations.
@en
P2093
P2860
P356
10.1136/BMJ.324.7352.1498
P407
P577
2002-06-01T00:00:00Z